Randomized Trial Evaluation of the Benefits and Risks of Menopausal Hormone Therapy Among Women 50–59 Years of Age

Overview of attention for article published in American Journal of Epidemiology, October 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (84th percentile)
Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

blogs: 1 blog
twitter: 5 X users

guideline: 1 clinical guideline source

Readers on

mendeley: 128 Mendeley

So far, Altmetric has seen 6 X posts from 5 X users, with an upper bound of 49,756 followers.

#TBT time! Ross L. Prentice, @TheDrAladdin, & colleagues examine the benefits and risks of menopausal hormone therapy using #RCT data from the the Women’s Health Initiative in this 2021 @AmJEpi article. read it here! ⬇️ @societyforepi https://t.co/sK9…

@AgnesWold @BMrck I övrigt så är datan kring hormoner under klimakteriet inte så solklara direkt. Tittar man på de yngre deltagarna från start så verkar det ge fördelar https://t.co/J8BSxG8haZ https://t.co/d850J4nXx3

Definitely check out this 2021 paper in @AmJEpi by Ross L. Prentice and collaborators from multiple institutes who studied the health benefits and risks of hormone replacement therapy in 27,347 healthy postmenopausal women as part of the @WHIStudy. ht…

RT @epipubs: Benefits and risks of menopausal hormone therapy: evaluating RCTs with 27,347 women aged 50–79 years at 40 US clinical centers…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 2 additional X posts.